Results 211 to 220 of about 39,319 (333)

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

, 2015
Ajai Chari, Saurabh Chhabra, Saad Z. Usmani, Sarah Larson, Rubén Niesvizky, Jeffrey Matous, Cristina Gasparetto, Beata Holkova, Matthew A. Lunning, Jason Valent, Larry D. Anderson, Chatchada Karanes, Long Kwei, L. Chang, Thorsten Graef, Elizabeth Bilotti, Kevin T. McDonagh   +16 more
openalex   +1 more source

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia [PDF]

, 2017
Lotta Hansson, Anna Asklid, Joris Diels, Sandra Eketorp-Sylvan, Johanna Repits, Frans Søltoft, Ulrich Jäger, Anders Österborg   +7 more
openalex   +1 more source

First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients. [PDF]

Hematol Oncol
Silkenstedt E, Dreyling M.
europepmc   +1 more source

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

, 2015
Patrick P. Ng, Daniel Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Chang   +5 more
openalex   +1 more source

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations [PDF]

, 2017
Patrizia Mondello, Elliott J. Brea, Elisa de Stanchina, Eneda Toska, Aaron Y. Chang, Myles Fennell, Venkatraman Seshan, Ralph Garippa, David A. Scheinberg, José Baselga, Hans‐Guido Wendel, Anas Younes   +11 more
openalex   +1 more source

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells. [PDF]

Blood Adv
Kost SEF, Saleh A, Brown J, Yuan SH, Kuzio B, Yang L, Banerji V, Gibson SB, Johnston JB, Katyal S.   +9 more
europepmc   +1 more source

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib [PDF]

, 2017
Cecelia Miller, Amy S. Ruppert, Nyla A. Heerema, Kami J. Maddocks, Jadwiga Labanowska, H Breidenbach, Gerard Lozanski, Weiqiang Zhao, Amber Gordon, Jeffrey A. Jones, Joseph M. Flynn, Samantha Jaglowski, Leslie A. Andritsos, Kristie A. Blum, Farrukh T. Awan, Kerry A. Rogers, Michael R. Grever, Amy J. Johnson, Lynne V. Abruzzo, Erin Hertlein, James S. Blachly, Jennifer A. Woyach, John C. Byrd   +22 more
openalex   +1 more source

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

, 2016
Marco Ruella, Saad S. Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nuñez-Cruz, Michael Klichinsky, Omkar U. Kawalekar, Michael C. Milone, Simon F. Lacey, Anthony R. Mato, Stephen J. Schuster, Michael Kalos, Carl H. June, Saar Gill, Mariusz A. Wasik   +18 more
openalex   +1 more source

INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS [PDF]

, 2017
Thomas J. Kipps, Graeme Fraser, Steven Coutré, Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, John C. Byrd, Susan O’Brien, M.S. Dilhuydy, Peter Hillmen, Ulrich Jaeger, Carol Moreno, Paula Cramer, Stephan Stilgenbauer, A.A. Chanan‐Khan, Michelle Mahler, Mariya Salman, Minghua Cheng, Anil Londhe, Joi Ninomoto, Angela Howes, Danelle F. James, Michael Hallek   +22 more
openalex   +1 more source